This is a working overview of thymosin beta-4, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Morea transitioned to production in 2012 with the erotic thriller Jism 2, which starred Sunny Leone in her Bollywood debut and performed well commercially. He appeared as Anand Joshi in Happy New Year (2014) and made cameo in Alone (2015).
Anguished, she and the others are forced to run, as a dropship, CP officers, and an Overwatch soldier chase after them. They are able to lose them, escaping into an old canal tunnel. As they try to catch their breath within the tunnel, Julia is suddenly attacked by a headcrab. Ian and Derek try to get it off of her head, but when another horde of zombies appear, they are forced to fend them off instead. At that point, the Citadel's dark energy core explodes. City 17 is decimated to rubble, and the blinding blue light from the explosion fills the tunnel from a skylight in the roof. Flashbacks from previous events suddenly appear among the beams of light, recalling when David had given Julia the pistol. The scene returns to Julia, who pulls out the pistol, reloads it, and shoots the headcrab off of her. Derek helps her to her feet, and the three of them run for the tunnel exit as the film ends.
Styrene can be obtained in one stage if this reaction is conducted at elevated temperatures (315–440 °C (599–824 °F)) and pressures (0.35–0.7 MPa (51–102 psi)), in presence of an aluminosilicate catalyst.
Norman Geras (25 August 1943 – 18 October 2013); political theorist of Rhodesian Jewish origin; Professor Emeritus of Politics at the University of Manchester; author of over ten scholarly and historical texts, mostly focused on radical politics; contributed to analysis of Karl Marx in Marx and Human Nature; in 2006, he was one of the principal authors of the Euston Manifesto. Martin Gilbert (25 October 1936 – 3 February 2015); historian and honorary Fellow of Merton College, Oxford; author of 88 books, including works on Winston Churchill, the 20th century, and Jewish history including the Holocaust; was a member of the Chilcot Inquiry into Britain's role in the Iraq War; noted for his endorsement of Bat Ye'or and Eurabia theory, providing comment for her book, stating that the theory "is 100 percent accurate". One of Gilbert's last books, In Ishmael's House: A History of the Jews in Muslim Lands cited Ye'or with approval several times. Morris Ginsberg FBA (14 May 1889 – 31 August 1970) British sociologist and prolific author who played a key role in the development of the discipline of sociology. He served as editor of The Sociological Review in the 1930s and later became the founding chairman of the British Sociological Association in 1951 and its first President (1955–1957). He was president of the Aristotelian Society from 1942 to 1943, and helped draft the UNESCO 1950 statement titled The Race Question.
Sources: en.wikipedia.org
== Traditional use == Skullcaps are used in traditional medicine, such as in traditional Chinese medicine. The root of Scutellaria baicalensis – a common component of many preparations – is marketed in volumes that have led to the overexploitation of the wild plant. Its rarity has led to an increase in price, and encouraged the adulteration of the product with other species of Scutellaria. In 1773, Scutellaria lateriflora became a common treatment in North America for the hysteria and hydrophobia caused by rabies. Today it is still a popular medicinal herb. It is widely available as a commercial product used in western herbalism. The plant reportedly commands prices of $16 to $64 per pound dry weight.
The pharmacology of bicalutamide is the study of the pharmacodynamic and pharmacokinetic properties of the nonsteroidal antiandrogen (NSAA) bicalutamide. In terms of pharmacodynamics, bicalutamide acts as a selective antagonist of the androgen receptor (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT). It has no capacity to activate the AR. It does not decrease androgen levels and has no other important hormonal activity. The medication has progonadotropic effects due to its AR antagonist activity and can increase androgen, estrogen, and neurosteroid production and levels. This results in a variety of differences of bicalutamide monotherapy compared to surgical and medical castration, such as indirect estrogenic effects and associated benefits like preservation of sexual function and drawbacks like gynecomastia. Bicalutamide can paradoxically stimulate late-stage prostate cancer due to accumulated mutations in the cancer. When used as a monotherapy, bicalutamide can induce breast development in males due to its estrogenic effects. Unlike other kinds of antiandrogens, it may have less adverse effect on the testes and fertility. In terms of pharmacokinetics, bicalutamide is well-absorbed when taken by mouth. However, absorption diminishes at higher dosages. It reaches maximal constant levels after 4 to 12 weeks of therapy. Bicalutamide shows extensive plasma protein binding, mainly to albumin. It crosses the blood–brain barrier and exerts effects in the central nervous system.
==== International PKU Day ==== The International PKU Day was launched in 2013 and is taking place on 28 June every year. It was inspired by the Rare Disease Day and should increase the awareness for Phenylketonuria to get featured in news. This date was chosen because of the birthdays of both Robert Guthrie (born 28 June 1916) and Horst Bickel (born 28 June 1918). As both of these people had a tremendous impact on the dietary treatment for Phenylketonuria the date proved to be the best option. In subsequence, the Robert Guthrie Memorial site was launched.
== External links == Suttas Mahā Nidāna Sutta at dhammatalks.org SN 12.1: Paticca-samuppada-vibhanga Sutta SN 12.23: Upanisa Sutta, translation by Bhikkhu Thanissaro SN 12.23: Upanisa Sutta, translation and exposition by Bhikkhu Bodhi Commentaries Pratītyasamutpāda by Alawwe Anōmadassi Thero Dependent Origination: the Buddhist Law of Conditionality, by Prayudh Payutto Paticcasamuppada: Practical Dependent Origination, by Buddhadasa The Doctrine of Paticcasamuppada, U Than Daing A Discourse on Paticcasamuppada, Mahasi Sayadaw The Shape of Suffering: A study of Dependent Co-arising, Bhikkhu Thanissaro (2008) Educational Resources
=== Therapeutics === The small size and stability profile of Affimers combined with their human origin confer drug-like properties. This may represent advantages over antibodies in terms of tissue penetration, for example in solid tumours where Avacta are developing PD-L1 inhibitors as alternatives to Opdivo and Yervoy, though requires half life modification to prevent rapid excretion through the kidney. Affimers can be conjugated to form multimers for the design of therapeutics. Examples include the production of multi-specific Affimer molecules to albumin binders to increase their half-life in vivo and for use as the targeting moiety in chimeric receptors or modified to carry a toxin in Affimer-drug conjugates. Affimers as therapeutics are in discovery and preclinical development to tackle cancer, both via CAR-T cell therapy and as checkpoint inhibitors. Early studies using ex vivo human samples showed low immunogenicity associated with the Affimer scaffold, at levels comparable to a marketed antibody therapeutic. Furthermore, initial preclinical studies showed good efficacy and tolerability of the anti-PDL1 immuno-oncology Affimers in mice. It is anticipated that IND filing for the first Affimer therapeutic will occur in 2023.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.